Review
doi: 10.1517/14712598.7.8.1257.
CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy
Affiliations
- PMID: 17696823
- DOI: 10.1517/14712598.7.8.1257
Item in Clipboard
Review
CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy
Expert Opin Biol Ther.
2007 Aug.
Abstract
Stimulation of toll-like receptor (TLR)9 activates human plasmacytoid dendritic cells and B cells, and induces potent innate immune responses in preclinical tumor models and in patients. CpG oligodeoxynucleotides (ODNs) are TLR9 agonists that show promising results as vaccine adjuvants and in the treatment of cancers, infections, asthma and allergy. PF-3512676 (ProMune) was developed as a TLR9 agonist for the treatment of cancer as monotherapy and as an adjuvant in combination with chemo- and immunotherapy. Phase I and II trials have tested this drug in several hematopoietic and solid tumors. Pfizer has initiated Phase III trials to test PF-3512676 in combination with standard chemotherapy for non-small-cell lung cancer.
Similar articles
-
CpG 7909: PF 3512676, PF-3512676.Drugs R D. 2006;7(5):312-6. doi: 10.2165/00126839-200607050-00004. Drugs R D. 2006. PMID: 16922592 Review.
-
CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer.BioDrugs. 2009;23(6):361-75. doi: 10.2165/11316930-000000000-00000. BioDrugs. 2009. PMID: 19894778 Review.
-
Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.Adv Drug Deliv Rev. 2009 Mar 28;61(3):195-204. doi: 10.1016/j.addr.2008.12.008. Epub 2009 Jan 13. Adv Drug Deliv Rev. 2009. PMID: 19211030 Review.
-
Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation.BioDrugs. 2007;21(6):387-401. doi: 10.2165/00063030-200721060-00006. BioDrugs. 2007. PMID: 18020622 Review.
-
Technology evaluation: CpG-7909, Coley.Curr Opin Mol Ther. 2003 Oct;5(5):553-9. Curr Opin Mol Ther. 2003. PMID: 14601526 Clinical Trial.
Cited by
-
Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors.Cancer Res. 2014 Aug 1;74(15):4042-52. doi: 10.1158/0008-5472.CAN-13-2685. Epub 2014 May 8. Cancer Res. 2014. PMID: 24812273 Free PMC article.
-
Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity.Cancer Res. 2010 Sep 15;70(18):7209-20. doi: 10.1158/0008-5472.CAN-10-0905. Epub 2010 Sep 7. Cancer Res. 2010. PMID: 20823152 Free PMC article.
-
Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis.BMC Cancer. 2010 Dec 3;10:665. doi: 10.1186/1471-2407-10-665. BMC Cancer. 2010. PMID: 21129170 Free PMC article.
-
Gut microbiota: impacts on gastrointestinal cancer immunotherapy.Gut Microbes. 2021 Jan-Dec;13(1):1-21. doi: 10.1080/19490976.2020.1869504. Gut Microbes. 2021. PMID: 33435800 Free PMC article. Review.
-
Re-polarizing Myeloid-derived Suppressor Cells (MDSCs) with Cationic Polymers for Cancer Immunotherapy.Sci Rep. 2016 Apr 14;6:24506. doi: 10.1038/srep24506. Sci Rep. 2016. PMID: 27074905 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
